Characterization of Individuals With Difficult-to-Control Type 2 Diabetes and Post-Dexamethasone Suppression Test Cortisol Values <1.2, 1.2–1.8, and >1.8 μg/dL: Findings From the CATALYST Part 1 Study
Summary
- The findings from CATALYST Part 1 suggest that the glycemic and cardiovascular risk associated with endogenous hypercortisolism presents as a spectrum across post-dexamethasone suppression test (DST) cortisol levels
- Participant subgroups with DST cortisol 1.2–1.8 μg/dL and >1.8 μg/dL appeared to have many similarities in terms of glucose-lowering medication use, cardiac comorbidities, and renal comorbidities vs the subgroup with post-DST cortisol <1.2 μg/dL
- Use of newer glucose-lowering medication classes, such as sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists, and combinations of these newer classes did not differ significantly between participants with post-DST cortisol 1.2–1.8 μg/dL vs >1.8 μg/dL
- The prevalence of cardiac comorbidities (except for congestive heart failure) also did not differ significantly for participants with post-DST cortisol 1.2–1.8 μg/dL vs >1.8 μg/dL
- Compared with participants with post-DST cortisol <1.2 μg/dL, the use of newer glucose lowering medication classes and cardiac comorbidities were significantly more common in participants with post-DST cortisol of either 1.2–1.8 μg/dL or >1.8 μg/dL